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The development of the CRISPR-Cas platform for genome
editing has greatly simplified the process of making
targeted genetic modifications. Applications of genome
editing are expected to have a substantial impact on
human therapies through the development of better
animal models, new target discovery, and direct
therapeutic intervention.Like the earlier reagents, all the Cas9–sgRNA com-Genome editing tools
Progress in biomedical research and its applications
depends to a large extent on the methods available to
investigate and manipulate cells and organisms. Until
relatively recently, we had very limited capability to
make intentional modifications to specific genes. This
changed with the advent of programmable nucleases,
which can induce very high levels of modification in ar-
bitrarily selected genomic targets. First the zinc-finger
nucleases (ZFNs), then transcription activator-like
effector nucleases (TALENs), and most recently
CRISPR-Cas nucleases (derived from clustered regularly
interspaced short palindromic repeat (CRISPR) and
CRISPR-associated (Cas) loci) have opened the door to
making targeted genome alterations.
Remarkably, the essential CRISPR-Cas components
were identified only a little over 4 years ago [1]. These
consist of: 1) the Cas9 protein, which cuts DNA at a
site determined by 2) a single-guide RNA (sgRNA) that
carries a sequence (sometimes called the protospacer)
that matches the DNA target, and (3) a short sequence
in the target called the protospacer-adjacent motif
(PAM) that is required for Cas9 binding. With experi-
ence from ZFNs and TALENs as a model, editing of
genomic targets using CRISPR-Cas was quickly under-
taken with resounding success [2]. The rapid adoptionCorrespondence: dana@biochem.utah.edu
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does not have to be redesigned for each new target; tar-
get recognition is mediated simply by base pairing be-
tween the sgRNA and the target; production of new
sgRNAs is very easy; and the system can be multiplexed
by providing multiple sgRNAs. A number of variants of
Cas9 are now available, each with potentially beneficial
properties.
plex does is make a break in the genomic DNA target.
The consequences of this break are the result of cellu-
lar DNA repair processes. Local, short insertions and
deletions (indels) occur as a result of inaccurate non-
homologous end joining (NHEJ). Sequence replace-
ments can be introduced by homology-directed repair
(HDR) with a DNA template supplied with the nucle-
ase (Fig. 1). Both processes—local mutagenesis and
sequence replacements—have obvious utility.
The CRISPR-Cas reagents have proven to be remark-
ably efficient in making genome modifications in a wide
range of organisms and experimental settings. There
has been concern, however, about specificity. While
modifying the intended target, is Cas9 also introducing
mutations at off-target sites? Changes in the sgRNA, in
Cas9, and in delivery methods can enhance specificity
[3], and these are highly relevant to human uses of the
technology.Clinical uses: research
All research has the potential to have an impact on
clinical practice, but here I focus on two broad categor-
ies: disease models and target identification. A key ad-
vance provided by genome editing has been the ability
to extend models of human genetic diseases beyond
mice and other common laboratory organisms.
Disease-causing and predisposing mutations have been
introduced into non-human primates and into large
mammals with anatomic and physiologic characteristics
more similar to humans. Among many examples,le is distributed under the terms of the Creative Commons Attribution 4.0
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Fig. 1 Illustration of the repair consequences of targeted DNA
cleavage. The red arrow represents the targeted break at a single
chromosomal site made by CRISPR-Cas (or zinc-finger nucleases
(ZFNs) or transcription activator-like effector nucleases (TALENs)).
The expanded view shows the break in the presence of a repair
template (magenta). The break can be repaired by non-homologous
end joining (NHEJ), leading to local insertions and deletions (indels)
(blue star), or by homology-directed repair (HDR), incorporating
sequences from the donor template. In most eukaryotic cells, NHEJ
predominates, even in the presence of a homologous template. Because
correction with donor sequences is often desired, considerable research
is currently directed toward altering that balance
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injection of CRISPR-Cas materials directly into fertil-
ized eggs [4]. Pigs with a predisposition to cardiac,
neurological, and many other diseases have been cre-
ated both by embryo injection and by somatic cell
nuclear transfer [5]. These disease models facilitate the
testing of various therapeutic approaches: pharmaco-
logical, nutritional, and genetic.
Broad screens with CRISPR-Cas are being used to
identify new therapeutic targets. One example identified
cellular genes required for infection by West Nile virus
[6]. Other studies are directed toward defining pathways
on which particular cancer cells uniquely depend for
their growth. Discovery of novel targets will facilitate fo-
cused screens for novel therapies, including small mol-
ecule drugs.Clinical uses: somatic therapy
When a clear genetic contribution has been identified
for any particular condition, genome editing of a pa-
tient’s own cells can be considered as a possible therapy.
In fact, a clinical trial has been under way for several
years for acquired immune deficiency syndrome (AIDS),
using ZFNs to target the CCR5 gene that encodes a co-
receptor required by most strains of HIV-1 to infect T
cells. Initial results showed efficient knockout of CCR5,persistence of modified cells, and absence of adverse ef-
fects [7].
This example illustrates the most accessible approach
to somatic therapy by genome editing: manipulation of
cells ex vivo and their return to the patient. For persist-
ent benefit, the therapeutic modification should be made
in long-term repopulating cells, such as hematopoietic
stem cells. A variety of approaches is being pursued in
the realm of hemoglobinopathies, including targeted
correction of the sickle cell mutation and persistence of
fetal hemoglobin [8]. As other stem cell approaches are
mastered, including induced pluripotent stem cells from
patients, genome editing can be applied to them as well.
Prospects for in vivo genome editing are less rosy due to
the challenges of delivering the materials effectively to
the target tissues, but there is active research in this
area.
Genome editing is being used to improve the perform-
ance of cell-based immunotherapies [9]. TALENs were
used to produce ‘universal donor’ T cells, which were
applied successfully to treat a young leukemia patient.
Two recently approved clinical trials use CRISPR-Cas to
inactivate the gene encoding programmed cell death
protein PD-1 (which functions as an immune checkpoint
and downregulates the immune system by preventing T-
cell activation) to enhance the effectiveness of chimeric
antigen receptor (CAR) T-cell therapies. In each of these
cases, as with the CCR5 trial, nucleases are being used
to create targeted indels that inactivate a gene. Making
targeted corrections by HDR is less efficient and more
challenging, so advances in this area will be required.Clinical uses: germline modifications
Some genetic diseases do not readily lend themselves to
somatic therapy. No effective gene therapy exists for cys-
tic fibrosis, despite much effort, since the responsible
gene was identified in the late 1980s. Cystic fibrosis af-
fects multiple organs, and mortality usually results from
defects in relatively inaccessible cells deep in the lung;
thus, delivery of the therapeutic gene is very challenging.
In cases where somatic approaches do not look prom-
ising, researchers are considering making permanent
changes to the genomes of human embryos. From a
medical perspective, this has the advantage that gene
correction will be permanent; neither the treated person
nor any of his/her descendants will carry the disease al-
lele. In principle, the procedure would involve manipu-
lating embryos at a very early stage, in conjunction with
in vitro fertilization. Two groups in China have pub-
lished papers describing early steps in producing such
modifications [10]. In these studies, and in other efforts
just getting under way, there was no intent to create a
pregnancy, and the embryos were never implanted.
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genome has generated considerable concern. Do we know
enough about human biology to predict confidently all the
consequences of such modifications? Are the procedures
safe enough, or will they induce unwanted mutations and
consequences? Will the technology be used to attempt
“enhancements”—greater intelligence, athletic prowess, at-
tractive physical features—rather than disease treatments?
Concluding remarks
My view is that genome editing technology is simple
enough that it will certainly be used for reproductive
editing in the foreseeable future. It should not be done
today because the methods are neither efficient nor safe
enough to ensure beneficial outcomes. Nonetheless,
there will be interest from patients and advocacy groups
in employing technology that can help prevent debilitat-
ing diseases. The role of research should be to make im-
provements that will ensure safety and efficacy. This will
require research with human embryos, under very strin-
gent criteria for approval and monitoring. Key issues will
be, first, minimizing off-target effects. Considerable pro-
gress has been made in this area, but the issue will have
to be assessed specifically for each new target. Second, it
will be important to improve the efficiency of targeted
correction by HDR, perhaps by inhibition of the NHEJ
pathway. And last, researchers need to develop effective
delivery methods for in vivo treatments with CRISPR-
Cas. Viral vectors show promise, but the targeting and
efficiency of these vectors can still be improved.
Equally important is careful consideration of the soci-
etal and ethical issues raised by both somatic and re-
productive genome editing. Beyond assessing our
comfort with gene manipulation technology, we must
also consider what genetic conditions are legitimate
candidates for modification and how the benefits of any
therapy will be distributed to the people who need it
most. As an example of the former issue, is hereditary
deafness a condition that should be eliminated? Most deaf
people are very high-functioning, and many would not
identify their situation as needing to be fixed. Sickle cell
disease falls into the latter category. A good deal of re-
search is directed at modifying patient stem cells, but the
approaches all involve laboratory manipulations that are
time-consuming, expensive, and not readily transported to
regions of the world where the disease is endemic. How
can a genetic therapy be made widely available?
International discussions and assessments of genome
editing and its implications are under way, but are still
at early stages. The prospects for beneficial medical uses
of genome editing are bright, and research is being pur-
sued very broadly. How these benefits are ultimately
employed will depend on efforts both inside and outside
the laboratory and the clinic.Abbreviations
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